Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab

Introduction: Myelomatous pleural effusion (MPE) and pericardial involvement are rare manifestations of multiple myeloma (MM), occurring in less than 1% of cases and carrying historically poor prognoses. We present a unique case where both these rare serous cavity manifestations occurred...

Full description

Saved in:
Bibliographic Details
Main Authors: Deena Mudawi, Abdulrahman F. Al-Mashdali, Ahmad Tawalbeh, Lajos Szabados, Dina Sameh Soliman, Shehab Fareed
Format: Article
Language:English
Published: Karger Publishers 2025-05-01
Series:Case Reports in Oncology
Online Access:https://karger.com/article/doi/10.1159/000545930
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850251952022093824
author Deena Mudawi
Abdulrahman F. Al-Mashdali
Ahmad Tawalbeh
Lajos Szabados
Dina Sameh Soliman
Shehab Fareed
author_facet Deena Mudawi
Abdulrahman F. Al-Mashdali
Ahmad Tawalbeh
Lajos Szabados
Dina Sameh Soliman
Shehab Fareed
author_sort Deena Mudawi
collection DOAJ
description Introduction: Myelomatous pleural effusion (MPE) and pericardial involvement are rare manifestations of multiple myeloma (MM), occurring in less than 1% of cases and carrying historically poor prognoses. We present a unique case where both these rare serous cavity manifestations occurred sequentially in the same patient, demonstrating the evolving treatment landscape with novel targeted therapies. Case Presentation: A 42-year-old Asian female presented with left shoulder pain and swelling, leading to the diagnosis of IgG lambda MM with extensive extramedullary disease. After initial partial response to D-VRD therapy, she developed MPE with complete left lung collapse. Following failure of second-line KPD-PACE therapy, she received teclistamab, achieving complete metabolic and morphological response documented by PET-CT. After maintaining remission for 10 months, she experienced relapse with pericardial involvement presenting as cardiac tamponade. Conclusion: The patient demonstrated an unprecedented response to BCMA-targeted therapy with teclistamab, achieving complete remission that lasted 10 months – more than doubling the historical median survival of 4 months for MPE. Flow cytometry proved instrumental in rapid diagnosis, showing 11% lambda monotypic plasma cells in the pleural fluid. The subsequent pericardial involvement after initial complete response highlighted the persistent challenges in managing extramedullary disease. This case represents the first documented instance of sequential MPE and pericardial involvement in MM, demonstrating the potential of novel targeted therapies, particularly BCMA-directed approaches, in extending survival and improving outcomes in these rare but aggressive disease manifestations.
format Article
id doaj-art-1b95fab4ee054d2f9d3322d3f68341c3
institution OA Journals
issn 1662-6575
language English
publishDate 2025-05-01
publisher Karger Publishers
record_format Article
series Case Reports in Oncology
spelling doaj-art-1b95fab4ee054d2f9d3322d3f68341c32025-08-20T01:57:47ZengKarger PublishersCase Reports in Oncology1662-65752025-05-0118162062910.1159/000545930Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with TeclistamabDeena MudawiAbdulrahman F. Al-MashdaliAhmad TawalbehLajos Szabadoshttps://orcid.org/0000-0002-1283-7719Dina Sameh SolimanShehab Fareed Introduction: Myelomatous pleural effusion (MPE) and pericardial involvement are rare manifestations of multiple myeloma (MM), occurring in less than 1% of cases and carrying historically poor prognoses. We present a unique case where both these rare serous cavity manifestations occurred sequentially in the same patient, demonstrating the evolving treatment landscape with novel targeted therapies. Case Presentation: A 42-year-old Asian female presented with left shoulder pain and swelling, leading to the diagnosis of IgG lambda MM with extensive extramedullary disease. After initial partial response to D-VRD therapy, she developed MPE with complete left lung collapse. Following failure of second-line KPD-PACE therapy, she received teclistamab, achieving complete metabolic and morphological response documented by PET-CT. After maintaining remission for 10 months, she experienced relapse with pericardial involvement presenting as cardiac tamponade. Conclusion: The patient demonstrated an unprecedented response to BCMA-targeted therapy with teclistamab, achieving complete remission that lasted 10 months – more than doubling the historical median survival of 4 months for MPE. Flow cytometry proved instrumental in rapid diagnosis, showing 11% lambda monotypic plasma cells in the pleural fluid. The subsequent pericardial involvement after initial complete response highlighted the persistent challenges in managing extramedullary disease. This case represents the first documented instance of sequential MPE and pericardial involvement in MM, demonstrating the potential of novel targeted therapies, particularly BCMA-directed approaches, in extending survival and improving outcomes in these rare but aggressive disease manifestations. https://karger.com/article/doi/10.1159/000545930
spellingShingle Deena Mudawi
Abdulrahman F. Al-Mashdali
Ahmad Tawalbeh
Lajos Szabados
Dina Sameh Soliman
Shehab Fareed
Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab
Case Reports in Oncology
title Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab
title_full Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab
title_fullStr Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab
title_full_unstemmed Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab
title_short Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab
title_sort sequential myelomatous pleural and pericardial effusions in multiple myeloma a case report demonstrating extended survival with teclistamab
url https://karger.com/article/doi/10.1159/000545930
work_keys_str_mv AT deenamudawi sequentialmyelomatouspleuralandpericardialeffusionsinmultiplemyelomaacasereportdemonstratingextendedsurvivalwithteclistamab
AT abdulrahmanfalmashdali sequentialmyelomatouspleuralandpericardialeffusionsinmultiplemyelomaacasereportdemonstratingextendedsurvivalwithteclistamab
AT ahmadtawalbeh sequentialmyelomatouspleuralandpericardialeffusionsinmultiplemyelomaacasereportdemonstratingextendedsurvivalwithteclistamab
AT lajosszabados sequentialmyelomatouspleuralandpericardialeffusionsinmultiplemyelomaacasereportdemonstratingextendedsurvivalwithteclistamab
AT dinasamehsoliman sequentialmyelomatouspleuralandpericardialeffusionsinmultiplemyelomaacasereportdemonstratingextendedsurvivalwithteclistamab
AT shehabfareed sequentialmyelomatouspleuralandpericardialeffusionsinmultiplemyelomaacasereportdemonstratingextendedsurvivalwithteclistamab